Evidence map›Paper›PMID 39712406›Full record

ArticleProceedings (Baylor University. Medical Center)2025

Intragastric balloon adverse events: a comprehensive MAUDE database review.

Islam Mohamed, Jagadish Koyi, Husam Abu Suilik, Hazem Abosheiashaa, Fouad Jaber, Syed Hamaad Rahman, Dushyant Singh Dahiya, Ahmed Telbany, Omar T Ahmed, Yusuke Hashimoto

Abstract read
In one paragraph

Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Advances and future directions in endoscopic bariatric therapies.World journal of gastrointestinal endoscopy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Islam MohamedDepartment of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, USA.ORCID https://orcid.org/0000-0002-0740-8960
Jagadish KoyiDepartment of Internal Medicine, University of Missouri - Kansas City, Kansas City, Missouri, USA.
Husam Abu SuilikFaculty of Medicine, Hashemite University, Zarqa, Jordan.
Hazem AbosheiashaaDepartment of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fouad JaberDepartment of Gastroenterology and Hepatology, Baylor University, Houston, Texas, USA.
Syed Hamaad RahmanDepartment of Internal Medicine, Methodist Dallas Medical Center, Dallas, Texas, USA.
Dushyant Singh DahiyaDepartment of Gastroenterology and Hepatology, University of Kansas School of Medicine, Kansas City, Kansas, USA.
Ahmed TelbanyDepartment of Gastroenterology and Hepatology, University of New Mexico, Albuquerque, New Mexico, USA.
Omar T AhmedDepartment of Gastroenterology and Hepatology, University of Illinois - Chicago, Chicago, Illinois, USA.
Yusuke HashimotoDepartment of Gastroenterology and Hepatology, The University of Florida College of Medicine - Jacksonville, Jacksonville, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Endoscopic bariatric interventions are viable alternatives to traditional weight loss surgeries for patients with a body mass index between 30 and 40 kg/m Methods: A retrospective analysis using the Manufacturer and User Facility Device Experience (MAUDE) database examined device-related events and patient outcomes associated with various intragastric balloons from July 2017 to October 2023. Data analysis was performed using SPSS software to assess the reported events and their associations with specific types of intragastric balloons. Results: Our review included 1393 cases, revealing 1758 device malfunctions and 1760 patient complications. Deflation problems (25.31%) and balloon leakage or rupture (21.90%) were the most common device-related complications. Patient complications were primarily linked to the Orbera balloon, with implant failure (24.30%), abdominal pain (21.92%), and vomiting (21.26%) as leading adverse events. Conclusion: Our findings highlight the need for continuous surveillance, rigorous monitoring, and enhanced safety protocols for intragastric balloons.

Indexed as

Bariatric endoscopyendoscopygastric balloonnonsurgical weight loss

Identifiers

PMID39712406
PMCPMC11657097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.